SYRE / Spyre Therapeutics, Inc. - Insider Trading and Ownership Report - SEC Form 3, 4, 5

Spyre Therapeutics, Inc.
US ˙ NasdaqGS ˙ US00773J2024

Deler fremragende 86,259,358 shares
Insideraktier5.328.968 shares
Insider ejerskab6,18 %
Total Insiders41
Insider-stemningsscore

Insider Sentiment Score viser, at virksomhederne bliver købt af virksomheders insidere.

Det er resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af insider-akkumulering. Scoringsmodellen bruger en kombination af nettoantallet af insidere, der har købt de foregående 90 dage, det samlede antal aktier købt som en procentdel af float og det samlede antal aktier ejet af insidere. Tallet går fra 0 til 100, hvor højere tal indikerer et højere niveau af akkumulering for sine jævnaldrende, og 50 er gennemsnittet.

Opdateringsfrekvens: Dagligt

Se Insiders Top Picks, som giver en liste over virksomheder med den højeste insider-akkumulering.

Officers sentiment score

Officer Sentiment Score finder virksomheder, der bliver købt af Corporate Officers.

Per definition er Corporate Officers Corporate Insiders, men i modsætning til nogle af de andre Insiders (10 % aktionærer og bestyrelsesmedlemmer), arbejder officerer for virksomheden på daglig basis, og de bruger deres egne penge, når de handler . (10 % aktionærer og bestyrelsesmedlemmer er ofte fondsforvaltere, der administrerer andres penge.) Som sådan er insiderhandler foretaget af embedsmænd meget mere betydningsfulde og bør behandles passende.

Ligesom Insider Sentiment Score er Officer Sentiment Score resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af officerakkumulering.

Opdateringsfrekvens: Dagligt

Se Insiders Top Picks, som giver en liste over virksomheder med højeste insider-stemning.

Nøgle Insider Metrics

Dette kort viser, hvordan virksomheden rangerer langs forskellige insider-metrics. Percentilrangen viser, hvordan denne virksomhed sammenligner sig med andre virksomheder på de amerikanske markeder. Højere placeringer er tegn på bedre situationer.

For eksempel er det generelt accepteret, at insider-køb er en positiv indikator, så virksomheder med flere insider-køb vil rangere højere end virksomheder med mindre insider-køb (eller endda insider-salg).

Netto antal insidere, der køber (rang)

-3 ( )
10253 out of 10986

Netto antal insidere, der køber, er det samlede antal insiders, der køber minus det samlede antal insiders, der har solgt inden for de sidste 90 dage. Percentilrangen vises her (spænder fra 0 til 100%).

Procent af float købt af insidere (rangering)

-0.222% ( )
10448 out of 10856

Procent af float købt af insidere er det samlede antal aktier købt af insidere minus det samlede antal aktier solgt af insidere inden for de sidste 90 dage, divideret med den samlede float og ganget med 100.

Insiderhandelsdiagram

Spyre Therapeutics, Inc. insiderhandler er vist i følgende diagram. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Generelt er det generelt ulovligt for insidere at foretage handler i deres virksomheder baseret på væsentlige, ikke-offentlige oplysninger. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4.

Insiderliste og lønsomhedsmålinger

Denne tabel viser listen over kendte insidere og genereres automatisk fra arkiveringer, der er videregivet til SEC. Ud over navnene, den seneste titel og direktør, officer eller 10 % ejerbetegnelse giver vi de seneste offentliggjorte besiddelser. Derudover giver vi, når det er muligt, den historiske handelspræstation for insideren. Den historiske handelspræstation er et vægtet gennemsnit af præstationen af faktiske købstransaktioner på det åbne marked foretaget af insideren. For mere information om, hvordan dette beregnes, se dette YouTube-webinar.

See our leaderboard of most profitable insider traders.

Insider Gennemsnitlig fortjeneste (%) Aktier
Ejet
Dele
Justeret
Albers Jeffrey W. Director - [D] 27.360 27.360
Jonathan Alspaugh Chief Financial Officer - [O] 165.372 6.615
Baker Bros. Advisors Lp Director - [D] 3.094.590 123.784
Suzanne Louise Bruhn 28.100
Scott L Burrows Chief Financial Officer - [O] 97.994 97.994
Cox Russell J. Director - [D] 7.000 280
Fairmount Funds Management LLC Director - [D] 4.018.101 4.018.101
George Georgiou Director - [D] 175.861 7.034
Michael Thomas Henderson Director - [D] 168.606 168.606
Hanley Jr. Michael Conick Chief Commercial Officer - [O] 36.200 1.448
Henry Hebel 38.200
Samuel D Isaly 10% Owner - [10%] 1.469.524 58.781
James Paul Kastenmayer Interim CEO & General Counsel - [O] 8.000 320
Insider Gennemsnitlig fortjeneste (%) Aktier
Ejet
Dele
Justeret
V Bryan Lawlis 28.100
Eli & Co Lilly 10% Owner - [10%] 2.068.543 82.742
Alison Frances Lawton 0
Lilly Ventures Fund I LLC 10% Owner - [10%] 57.619 82.742
David George Lowe CEO and President, Director - [D] [O] 5.658 226
Ivana Magovcevic 28.100
Sandesh Mahatme 28.100
Ag Novartis 10% Owner - [10%] 2.175.314 87.013
Linda L Neuman Chief Medical Officer - [O] 4.000 160
Bioventures Ltd Novartis 10% Owner - [10%] 2.175.314 87.013
Orbimed Advisors Llc 10% Owner - [10%] 1.469.524 58.781
OrbiMed Capital GP V LLC 10% Owner - [10%] 1.469.524 58.781
Anthony Quinn President & CEO, Director - [D] [O] 550.540 22.022
Madduri Ravin Rao 25.000
Insider Gennemsnitlig fortjeneste (%) Aktier
Ejet
Dele
Justeret
Sandra Rojas-Caro 0
Scott W Rowlinson VP, Research - [O] 11.204 448
Aaron Schuchart Chief Business Officer - [O] 2.500 100
Armen Shanafelt Director, 10% Owner - [D] [10%] 150.000 6.000
Leslie Sloan 180.000
Sheldon Sloan Chief Medical Officer - [O] 0 0
Hunter C Smith 60.000
Marcio Souza Director - [D] 90.000 3.600
Joseph E Tyler VP, Manufacturing - [O] 42.428 1.697
Torres S. Edward 10% Owner - [10%] 115.238 4.610
Cameron Turtle Chief Executive Officer, Director - [D] [O] 612.540 612.540
Steven Weber VP, Controller&Princ Acctg Off - [O] 17.652 706
James Wooldridge 50.200
Charles N II York Chief Financial Officer and VP - [O] 34.787 1.391

Report errors via our new Insider Auditing Tool

Track Records af insiderkøb - Kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i SYRE / Spyre Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2022-08-25 Souza Marcio 90.000 0,5608 3.600 14,0200 50.472 77 38.5 88.128 174,61
2022-06-08 Hanley Jr. Michael Conick 28.200 0,7100 1.128 17,7500 20.022
2022-03-16 Quinn Anthony 80.079 2,3440 3.203 58,6000 187.705
2022-03-15 Quinn Anthony 42.417 1,8611 1.697 46,5275 78.942
2022-03-14 Quinn Anthony 67.472 1,9300 2.699 48,2500 130.221
2022-03-11 Alspaugh Jonathan 75.000 2,0800 3.000 52,0000 156.000
2022-03-11 Quinn Anthony 34.777 2,0640 1.391 51,6000 71.780
2021-12-13 Shanafelt Armen 14.685 3,6500 587 91,2500 53.600
2021-12-10 Shanafelt Armen 13.516 3,6500 541 91,2500 49.333

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SYRE / Spyre Therapeutics, Inc. Insider Trades
Track Records af insidersalg - Kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i SYRE / Spyre Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2025-09-02 Burrows Scott L 18.428 16,2600 18.428 16,2600 299.639 14 14.8200 -26.536 -8,86
2024-09-03 Burrows Scott L 18.531 28,1730 18.531 28,1730 522.074
2018-09-27 Schuchart Aaron 5.900 9,5000 236 237,5000 56.050
2018-09-27 Schuchart Aaron 100 9,5500 4 238,7500 955
2018-05-11 Novartis Bioventures Ltd 19.550 10,0600 782 251,5000 196.673
2018-05-10 Novartis Bioventures Ltd 22.725 10,1300 909 253,2500 230.204
2018-05-09 Novartis Bioventures Ltd 51.230 10,1100 2.049 252,7500 517.935
2018-05-08 Novartis Bioventures Ltd 26.557 10,0300 1.062 250,7500 266.367
2018-05-07 Novartis Bioventures Ltd 15.548 10,1100 622 252,7500 157.190

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SYRE / Spyre Therapeutics, Inc. Insider Trades
Transaktionshistorik

Klik på linkikonet for at se den fulde transaktionshistorik. Transaktioner, der rapporteres som en del af en automatisk handelsplan 10b5-1, vil have et X i kolonnen markeret 10b-5.

Fil
Dato
Handle
Dato
Form Insider Ticker Sikkerhedstitel Kode 10b5-1 Direkte Dyrke motion
Pris
Enhed
Pris
Enheder
Ændret
Værdi
Ændret (1K)
Tilbage
Muligheder
Tilbage
Aktier
2026-05-01 2026-05-01 4 Burrows Scott L SYRE Common Stock S - Sale D 71,3700 -12.500 -892 97.994
2026-05-01 2026-05-01 4 Burrows Scott L SYRE Common Stock M - Exercise D 14,5000 12.500 181 110.494
2026-05-01 2026-05-01 4 Turtle Cameron SYRE Common Stock S - Sale D 74,9600 -300 -22 612.540
2026-05-01 2026-05-01 4 Turtle Cameron SYRE Common Stock S - Sale D 74,2300 -1.700 -126 612.840
2026-05-01 2026-05-01 4 Turtle Cameron SYRE Common Stock S - Sale D 73,1400 -3.100 -227 614.540
2026-05-01 2026-05-01 4 Turtle Cameron SYRE Common Stock S - Sale D 71,7600 -1.000 -72 617.640
2026-05-01 2026-05-01 4 Turtle Cameron SYRE Common Stock S - Sale D 70,7700 -3.600 -255 618.640
2026-05-01 2026-05-01 4 Turtle Cameron SYRE Common Stock S - Sale D 69,5400 -5.300 -369 622.240
2026-05-01 2026-05-01 4 Sloan Sheldon SYRE Common Stock S - Sale D 75,3700 -400 -30 0
2026-05-01 2026-05-01 4 Sloan Sheldon SYRE Common Stock S - Sale D 74,6000 -5.059 -377 400
2026-05-01 2026-05-01 4 Sloan Sheldon SYRE Common Stock S - Sale D 73,7400 -10.358 -764 5.459
2026-05-01 2026-05-01 4 Sloan Sheldon SYRE Common Stock S - Sale D 72,9400 -12.777 -932 15.817
2026-05-01 2026-05-01 4 Sloan Sheldon SYRE Common Stock S - Sale D 71,5600 -8.777 -628 28.594
2026-05-01 2026-05-01 4 Sloan Sheldon SYRE Common Stock S - Sale D 70,6100 -19.656 -1.388 37.371
2026-05-01 2026-05-01 4 Sloan Sheldon SYRE Common Stock S - Sale D 69,5300 -21.306 -1.481 57.027
2026-05-01 2026-05-01 4 Sloan Sheldon SYRE Common Stock M - Exercise D 27,4600 78.333 2.151 78.333
2026-04-03 2026-04-01 4 Turtle Cameron SYRE Common Stock S - Sale D 49,9200 -2.656 -133 627.540
2026-04-03 2026-04-01 4 Turtle Cameron SYRE Common Stock S - Sale D 49,2000 -12.344 -607 630.196
2026-04-03 2026-04-01 4 Sloan Sheldon SYRE Common Stock S - Sale D 50,0000 -7.958 -398 0
2026-04-03 2026-04-01 4 Sloan Sheldon SYRE Common Stock M - Exercise D 21,6600 7.958 172 7.958
2026-04-03 2026-04-01 4 Burrows Scott L SYRE Common Stock S - Sale D 49,9800 -1.300 -65 97.994
2026-04-03 2026-04-01 4 Burrows Scott L SYRE Common Stock S - Sale D 49,2100 -6.200 -305 99.294
2026-04-03 2026-04-01 4 Burrows Scott L SYRE Common Stock M - Exercise D 14,5000 7.500 109 105.494
2026-03-03 2026-03-03 4 Burrows Scott L SYRE Common Stock S - Sale D 41,6600 -200 -8 97.994
2026-03-03 2026-03-03 4 Burrows Scott L SYRE Common Stock S - Sale D 40,5600 -2.300 -93 98.194
2026-03-03 2026-03-03 4 Burrows Scott L SYRE Common Stock M - Exercise D 14,5000 2.500 36 100.494
2026-03-03 2026-03-02 4 Turtle Cameron SYRE Common Stock S - Sale D 42,4900 -9.100 -387 642.540
2026-03-03 2026-03-02 4 Turtle Cameron SYRE Common Stock S - Sale D 41,7300 -5.900 -246 651.640
2026-02-04 2026-02-02 4 Turtle Cameron SYRE Common Stock S - Sale D 32,8700 -14.043 -462 657.540
2026-02-04 2026-02-02 4 Turtle Cameron SYRE Common Stock S - Sale D 31,8200 -957 -30 671.583
2026-01-23 2026-01-21 4 HENDERSON MICHAEL THOMAS SYRE Common Stock J - Other D 63.227 168.606
2026-01-06 2026-01-02 4 Turtle Cameron SYRE Common Stock S - Sale D 32,3900 -100 -3 671.907
2026-01-06 2026-01-02 4 Turtle Cameron SYRE Common Stock S - Sale D 31,7900 -2.191 -70 672.007
2026-01-06 2026-01-02 4 Turtle Cameron SYRE Common Stock S - Sale D 30,4700 -12.709 -387 674.198
2025-12-03 2025-12-01 4 Turtle Cameron SYRE Common Stock S - Sale D 29,8300 -4.005 -119 686.907
2025-12-03 2025-12-01 4 Turtle Cameron SYRE Common Stock S - Sale D 28,7300 -10.995 -316 690.912
2025-11-05 2025-11-03 4 Turtle Cameron SYRE Common Stock S - Sale D 23,6600 -16.845 -399 701.907
2025-11-05 2025-11-03 4 Turtle Cameron SYRE Common Stock S - Sale D 23,1300 -28.155 -651 718.752
2025-09-03 2025-09-02 4 Burrows Scott L SYRE Common Stock S - Sale D 16,2600 -18.428 -300 97.994
2025-01-14 2025-01-10 4 HENDERSON MICHAEL THOMAS SYRE Common Stock J - Other D 105.379 105.379
2024-11-08 2024-11-06 4 Albers Jeffrey W. By Sessions LLC SYRE Common Stock S - Sale I 36,7631 -6.700 -246 27.360
2024-10-28 2024-10-25 4 Albers Jeffrey W. By Sessions LLC SYRE Common Stock S - Sale I 36,4300 -300 -11 34.060
2024-09-05 2024-09-03 4 Burrows Scott L SYRE Common Stock S - Sale D 28,1730 -18.531 -522 116.422
2024-04-25 2024-04-25 4 Fairmount Funds Management LLC By Fairmount Healthcare Fund II L.P. SYRE Common Stock M - Exercise I 3.639.680 4.018.101
2024-02-20 2024-02-15 4 Turtle Cameron SYRE Common Stock A - Award D 9,8200 400 4 746.907
2023-12-29 2023-12-29 4 Fairmount Funds Management LLC By Peter Harwin SYRE Common Stock J - Other I 406.038 406.038
2023-12-29 2023-12-29 4 Fairmount Funds Management LLC By Tomas Kiselak SYRE Common Stock J - Other I 406.038 406.038
2023-12-29 2023-12-29 4 Fairmount Funds Management LLC By Fairmount Healthcare Co-Invest L.P. SYRE Common Stock J - Other I -3.435.480 0
2023-12-22 2023-12-22 4 Burrows Scott L SYRE Common Stock A - Award D 134.953 134.953
2023-12-08 2023-11-24 4/A Albers Jeffrey W. By Sessions LLC SYRE Common Stock C - Conversion I 34.360 34.360
2023-11-28 2023-11-24 4 Fairmount Funds Management LLC By Fairmount Healthcare Co-Invest L.P. AGLE Common Stock C - Conversion I 3.435.480 3.435.480
2023-11-27 2023-11-24 4 Turtle Cameron AGLE Common Stock C - Conversion D 723.440 746.507
2023-06-30 3 Turtle Cameron AGLE Common Stock D 576.699
2023-06-30 3 Fairmount Funds Management LLC By Fairmount Healthcare Fund LP( AGLE Common Stock I 276.082
2023-06-30 3 Fairmount Funds Management LLC By Fairmount Healthcare Fund II LP AGLE Common Stock I 9.184.458
2023-01-27 3 Neuman Linda L AGLE Common Stock D 4.000
2022-08-25 3 Kastenmayer James Paul AGLE Common Stock D 4.000
2022-08-25 2022-08-25 4 Souza Marcio AGLE Common Stock P - Purchase D 0,5608 90.000 50 90.000
2022-06-10 2022-06-08 4 Hanley Jr. Michael Conick AGLE Common Stock P - Purchase D 0,7100 28.200 20 36.200
2022-03-18 2022-03-16 4 Quinn Anthony AGLE Common Stock P - Purchase D 2,3440 80.079 188 550.540
2022-03-15 2022-03-15 4 Quinn Anthony AGLE Common Stock P - Purchase D 1,8611 42.417 79 473.461
2022-03-15 2022-03-14 4 Quinn Anthony AGLE Common Stock P - Purchase D 1,9300 67.472 130 431.044
2022-03-15 2022-03-11 4 Quinn Anthony AGLE Common Stock P - Purchase D 2,0640 34.777 72 363.572
2022-03-15 2022-03-11 4 Alspaugh Jonathan AGLE Common Stock P - Purchase D 2,0800 75.000 156 165.372
2022-02-22 2022-02-17 4 Quinn Anthony AGLE Employee Stock Option (right to buy) A - Award D 3,17 350.000 350.000
2022-02-22 2022-02-17 4 Weber Steven AGLE Employee Stock Option (right to buy) A - Award D 3,17 30.000 30.000
2022-02-22 2022-02-17 4 Sloan Leslie AGLE Employee Stock Option (right to buy) A - Award D 3,17 180.000 180.000
2022-02-22 2022-02-17 4 Hanley Jr. Michael Conick AGLE Employee Stock Option (right to buy) A - Award D 3,17 160.000 160.000
2022-02-22 2022-02-17 4 Alspaugh Jonathan AGLE Employee Stock Option (right to buy) A - Award D 3,17 170.000 170.000
2022-02-14 2021-10-20 5 Quinn Anthony AGLE Common Stock G - Gift I 10.000 208.845
2022-02-14 2021-10-20 5 Quinn Anthony AGLE Common Stock G - Gift D -10.000 328.795
2022-02-14 2021-10-18 5 Quinn Anthony AGLE Common Stock G - Gift I 23.809 208.845
2022-02-14 2021-10-18 5 Quinn Anthony AGLE Common Stock G - Gift D -23.809 328.795
2022-02-14 2021-10-14 5 Quinn Anthony AGLE Common Stock G - Gift I 175.036 208.845
2022-02-14 2021-10-14 5 Quinn Anthony AGLE Common Stock G - Gift D -175.036 328.795
2022-02-14 2018-12-28 5 Quinn Anthony AGLE Common Stock G - Gift I 57.450 57.450
2022-02-14 2018-12-28 5 Quinn Anthony AGLE Common Stock G - Gift D -57.450 328.795
2021-12-13 2021-12-13 4 Shanafelt Armen AGLE Common Stock P - Purchase D 3,6500 14.685 54 150.000
2021-12-13 2021-12-10 4 Shanafelt Armen AGLE Common Stock P - Purchase D 3,6500 13.516 49 135.315
2021-12-13 2021-12-09 4 Shanafelt Armen AGLE Common Stock P - Purchase D 3,6680 121.799 447 121.799
2021-12-13 2021-12-10 4 Quinn Anthony AGLE Common Stock P - Purchase D 3,7500 10.526 39 328.795
2021-12-13 2021-12-09 4 Quinn Anthony AGLE Common Stock P - Purchase D 3,7000 43.108 159 318.269
2021-12-13 2021-12-09 4 Alspaugh Jonathan AGLE Common Stock P - Purchase D 3,7200 50.000 186 90.372
2021-11-16 2021-11-12 4 Smith Hunter C AGLE Director Stock Option (right to buy) A - Award D 7,04 60.000 60.000
2021-08-18 2021-08-18 4 Alspaugh Jonathan AGLE Common Stock P - Purchase D 6,7222 7.200 48 40.372
2021-08-18 2021-08-17 4 Alspaugh Jonathan AGLE Common Stock P - Purchase D 6,4973 23.392 152 33.172
2021-08-18 2021-08-16 4 Alspaugh Jonathan AGLE Common Stock P - Purchase D 6,3676 9.780 62 9.780
2021-07-08 2021-07-06 4 Alspaugh Jonathan AGLE Employee Stock Option (right to buy) A - Award D 7,03 160.000 160.000
2021-06-22 2021-06-18 4 Souza Marcio AGLE Director Stock Option (right to buy) A - Award D 6,44 60.000 60.000
2021-06-10 2021-06-08 4 BAKER BROS. ADVISORS LP See Footnotes AGLE Non-Qualified Stock Option (right to buy) A - Award I 6,80 40.000 40.000
2021-06-09 2021-06-08 4 Mahatme Sandesh AGLE Director Stock Option (right to buy) A - Award D 6,80 40.000 40.000
2021-06-09 2021-06-08 4 Shanafelt Armen AGLE Director Stock Option (right to buy) A - Award D 6,80 40.000 40.000
2021-06-09 2021-06-08 4 Magovcevic Ivana AGLE Director Stock Option (right to buy) A - Award D 6,80 40.000 40.000
2021-06-09 2021-06-08 4 LAWLIS V BRYAN AGLE Director Stock Option (right to buy) A - Award D 6,80 40.000 40.000
2021-06-09 2021-06-08 4 Lawton Alison Frances AGLE Director Stock Option (right to buy) A - Award D 6,80 40.000 40.000
2021-06-09 2021-06-08 4 Cox Russell J. AGLE Director Stock Option (right to buy) A - Award D 6,80 40.000 40.000
2021-02-25 3 BAKER JULIAN See Footnotes AGLE Common Stock I 3.094.590
2021-02-25 3 BAKER JULIAN See Footnotes AGLE Common Stock I 315.516
2021-02-25 2021-02-23 4 BAKER BROS. ADVISORS LP See Footnotes AGLE Non-Qualified Stock Option (right to buy) A - Award I 7,11 47.200 47.200
2021-02-19 2021-02-17 4 Weber Steven AGLE Employee Stock Option (right to buy) A - Award D 7,35 50.000 50.000
2021-02-19 2021-02-17 4 Sloan Leslie AGLE Employee Stock Option (right to buy) A - Award D 7,35 160.000 160.000
2021-02-19 2021-02-17 4 Quinn Anthony AGLE Employee Stock Option (right to buy) A - Award D 7,35 330.000 330.000
2021-02-19 2021-02-17 4 Hanley Jr. Michael Conick AGLE Employee Stock Option (right to buy) A - Award D 7,35 135.000 135.000
2021-02-08 3 Weber Steven AGLE Common Stock D 17.652
2020-12-17 2020-12-15 4 Lawton Alison Frances AGLE Director Stock Option (right to buy) A - Award D 9,09 47.200 47.200
2020-06-10 2020-06-08 4 Shanafelt Armen AGLE Director Stock Option (right to buy) A - Award D 8,89 28.100 28.100
2020-06-10 2020-06-08 4 Bruhn Suzanne Louise AGLE Director Stock Option (right to buy) A - Award D 8,89 28.100 28.100
2020-06-10 2020-06-08 4 Cox Russell J. AGLE Director Stock Option (right to buy) A - Award D 8,89 28.100 28.100
2020-06-10 2020-06-08 4 LAWLIS V BRYAN AGLE Director Stock Option (right to buy) A - Award D 8,89 28.100 28.100
2020-06-10 2020-06-08 4 Magovcevic Ivana AGLE Director Stock Option (right to buy) A - Award D 8,89 28.100 28.100
2020-06-10 2020-06-08 4 Mahatme Sandesh AGLE Director Stock Option (right to buy) A - Award D 8,89 28.100 28.100
2020-05-04 2020-04-30 4 Quinn Anthony AGLE Common Stock P - Purchase D 4,7500 165.000 784 538.469
2020-02-19 2020-02-14 4 Rao Madduri Ravin AGLE Employee Stock Option (right to buy) A - Award D 8,15 25.000 25.000
2020-02-19 2020-02-14 4 Sloan Leslie AGLE Employee Stock Option (right to buy) A - Award D 8,15 100.000 100.000
2020-02-19 2020-02-14 4 York Charles N II AGLE Employee Stock Option (right to buy) A - Award D 8,15 126.000 126.000
2020-02-19 2020-02-14 4 Hanley Jr. Michael Conick AGLE Employee Stock Option (right to buy) A - Award D 8,15 25.000 25.000
2020-02-19 2020-02-14 4 Quinn Anthony AGLE Employee Stock Option (right to buy) A - Award D 8,15 301.000 301.000
2019-11-04 2019-11-01 4 Rao Madduri Ravin AGLE Employee Stock Option (right to buy) A - Award D 8,24 130.000 130.000
2019-10-23 2019-10-21 4 Hanley Jr. Michael Conick AGLE Employee Stock Option (right to buy) A - Award D 7,79 130.000 130.000
2019-10-07 2019-10-04 4 Quinn Anthony AGLE Stock Option (right to buy) M - Exercise D 6,31 -17.603 119.914
2019-10-07 2019-10-04 4 Quinn Anthony AGLE Stock Option (right to buy) M - Exercise D 5,46 -662 0
2019-10-07 2019-10-04 4 Quinn Anthony AGLE Common Stock M - Exercise D 6,3100 17.603 111 371.908
2019-10-07 2019-10-04 4 Quinn Anthony AGLE Common Stock M - Exercise D 5,4600 662 4 354.305
2019-06-14 2019-06-14 4 Quinn Anthony AGLE Common Stock P - Purchase D 6,2311 5.282 33 353.643
2019-06-14 2019-06-13 4 Quinn Anthony AGLE Common Stock P - Purchase D 6,1666 14.406 89 348.361
2019-06-14 2019-06-12 4 Quinn Anthony AGLE Common Stock P - Purchase D 6,1148 12.217 75 333.955
2019-06-07 2019-06-07 4 Bruhn Suzanne Louise AGLE Director Stock Option (right to buy) A - Award D 6,33 12.400 12.400
2019-06-07 2019-06-07 4 Cox Russell J. AGLE Director Stock Option (right to buy) A - Award D 6,33 12.400 12.400
2019-06-07 2019-06-07 4 Magovcevic Ivana AGLE Director Stock Option (right to buy) A - Award D 6,33 12.400 12.400
2019-06-07 2019-06-07 4 Mahatme Sandesh AGLE Director Stock Option (right to buy) A - Award D 6,33 12.400 12.400
2019-06-07 2019-06-07 4 Shanafelt Armen AGLE Director Stock Option (right to buy) A - Award D 6,33 12.400 12.400
2019-06-07 2019-06-07 4 LAWLIS V BRYAN AGLE Director Stock Option (right to buy) A - Award D 6,33 12.400 12.400
2019-05-22 2019-05-22 4 Quinn Anthony AGLE Common Stock P - Purchase D 6,8596 3.809 26 321.738
2019-05-22 2019-05-21 4 Quinn Anthony AGLE Common Stock P - Purchase D 6,8857 13.794 95 317.929
2019-05-22 2019-05-20 4 Quinn Anthony AGLE Common Stock P - Purchase D 6,5550 8.989 59 304.135
2019-05-17 2019-05-17 4 Quinn Anthony AGLE Common Stock P - Purchase D 6,6477 6.218 41 295.146
2019-05-17 2019-05-16 4 Quinn Anthony AGLE Common Stock P - Purchase D 6,8280 5.520 38 288.928
2019-05-17 2019-05-15 4 Quinn Anthony AGLE Common Stock P - Purchase D 6,7566 6.256 42 283.408
2019-05-17 2019-02-15 4 Quinn Anthony AGLE Common Stock P - Purchase D 7,0980 719 5 277.152
2019-03-08 2019-03-06 4 Sloan Leslie AGLE Employee Stock Option (right to buy) A - Award D 8,06 36.000 36.000
2019-03-01 2019-02-28 4 Quinn Anthony AGLE Stock Option (right to buy) A - Award D 8,36 280.000 280.000
2019-03-01 2019-02-28 4 Schuchart Aaron AGLE Employee Stock Option (right to buy) A - Award D 8,36 60.000 60.000
2019-03-01 2019-02-28 4 Wooldridge James AGLE Employee Stock Option (right to buy) A - Award D 8,36 50.200 50.200
2019-03-01 2019-02-28 4 York Charles N II AGLE Employee Stock Option (right to buy) A - Award D 8,36 87.600 87.600
2019-02-08 2019-02-06 4 Quinn Anthony AGLE Stock Option (right to buy) M - Exercise D 6,31 -7.433 137.517
2019-02-08 2019-02-06 4 Quinn Anthony AGLE Stock Option (right to buy) M - Exercise D 5,46 -1.323 662
2019-02-08 2019-02-06 4 Quinn Anthony AGLE Common Stock M - Exercise D 6,3100 7.433 47 276.433
2019-02-08 2019-02-06 4 Quinn Anthony AGLE Common Stock M - Exercise D 5,4600 1.323 7 269.000
2018-12-10 2018-12-07 4 Quinn Anthony AGLE Director Stock Option (right to buy) M - Exercise D 6,31 -18.584 144.950
2018-12-10 2018-12-07 4 Quinn Anthony AGLE Director Stock Option (right to buy) M - Exercise D 5,46 -3.306 1.985
2018-12-10 2018-12-07 4 Quinn Anthony AGLE Director Stock Option (right to buy) M - Exercise D 4,11 -150.000 0
2018-12-10 2018-12-07 4 Quinn Anthony AGLE Common Stock M - Exercise D 6,3100 18.584 117 267.677
2018-12-10 2018-12-07 4 Quinn Anthony AGLE Common Stock M - Exercise D 5,4600 3.306 18 249.093
2018-12-10 2018-12-07 4 Quinn Anthony AGLE Common Stock M - Exercise D 4,1100 150.000 616 245.787
2018-12-10 2018-08-15 4 Quinn Anthony AGLE Common Stock P - Purchase D 9,1300 994 9 95.787
2018-12-10 2018-02-15 4 Quinn Anthony AGLE Common Stock P - Purchase D 6,0200 2.000 12 94.793
2018-09-28 2018-09-27 4 Schuchart Aaron AGLE Common Stock S - Sale D 9,5000 -5.900 -56 2.500
2018-09-28 2018-09-27 4 Schuchart Aaron AGLE Common Stock S - Sale D 9,5500 -100 -1 8.400
2018-08-21 2018-08-17 4 Schuchart Aaron AGLE Employee Stock Option (right to buy) M - Exercise D 3,50 -8.500 91.500
2018-08-21 2018-08-17 4 Schuchart Aaron AGLE Common Stock M - Exercise D 3,5000 8.500 30 8.500
2018-08-15 2018-08-13 4 GEORGIOU GEORGE AGLE Director Stock Option (right to buy) M - Exercise D 4,73 -20.000 10.000
2018-08-15 2018-08-13 4 GEORGIOU GEORGE AGLE Director Stock Option (right to buy) M - Exercise D 7,28 -17.333 6.667
2018-08-15 2018-08-13 4 GEORGIOU GEORGE AGLE Common Stock M - Exercise D 4,7300 20.000 95 175.861
2018-08-15 2018-08-13 4 GEORGIOU GEORGE AGLE Common Stock M - Exercise D 7,2800 17.333 126 155.861
2018-07-20 2018-07-18 4 Quinn Anthony AGLE Employee Stock Option (right to buy) A - Award D 9,36 50.000 50.000
2018-07-20 2018-07-18 4 Quinn Anthony AGLE Employee Stock Option (right to buy) A - Award D 9,36 75.000 75.000
2018-07-20 2018-07-18 4 Quinn Anthony AGLE Employee Stock Option (right to buy) A - Award D 9,36 75.000 75.000
2018-07-20 2018-07-18 4 Quinn Anthony AGLE Employee Stock Option (right to buy) A - Award D 9,36 300.000 300.000
2018-07-17 2018-07-13 4 LAWLIS V BRYAN AGLE Director Stock Option (right to buy) A - Award D 8,78 36.800 36.800
2018-07-16 2018-07-12 4 Quinn Anthony AGLE Director Stock Option (right to buy) M - Exercise D 6,31 -14.866 163.534
2018-07-16 2018-07-12 4 Quinn Anthony AGLE Director Stock Option (right to buy) M - Exercise D 7,04 -24.000 0
2018-07-16 2018-07-12 4 Quinn Anthony AGLE Common Stock M - Exercise D 6,3100 14.866 94 92.793
2018-07-16 2018-07-12 4 Quinn Anthony AGLE Common Stock M - Exercise D 7,0400 24.000 169 77.927
2018-07-13 2018-07-11 4 Quinn Anthony AGLE Director Stock Option (right to buy) M - Exercise D 5,46 -3.307 5.291
2018-07-13 2018-07-11 4 Quinn Anthony AGLE Common Stock M - Exercise D 5,4600 3.307 18 53.927
2018-06-08 2018-06-07 4 Bruhn Suzanne Louise AGLE Director Stock Option (right to buy) A - Award D 10,28 18.400 18.400
2018-06-08 2018-06-07 4 Cox Russell J. AGLE Director Stock Option (right to buy) A - Award D 10,28 18.400 18.400
2018-06-08 2018-06-07 4 GEORGIOU GEORGE AGLE Director Stock Option (right to buy) A - Award D 10,28 18.400 18.400
2018-06-08 2018-06-07 4 Mahatme Sandesh AGLE Director Stock Option (right to buy) A - Award D 10,28 18.400 18.400
2018-06-08 2018-06-07 4 Shanafelt Armen AGLE Director Stock Option (right to buy) A - Award D 10,28 18.400 18.400
2018-05-14 2018-05-11 4 Novartis Bioventures Ltd AGLE Common Stock S - Sale D 10,0600 -19.550 -197 2.175.314
2018-05-11 2018-05-10 4 Novartis Bioventures Ltd AGLE Common Stock S - Sale D 10,1300 -22.725 -230 2.194.864
2018-05-11 2018-05-09 4 Novartis Bioventures Ltd AGLE Common Stock S - Sale D 10,1100 -51.230 -518 2.217.589
2018-05-09 2018-05-08 4 Novartis Bioventures Ltd AGLE Common Stock S - Sale D 10,0300 -26.557 -266 2.268.819
2018-05-09 2018-05-07 4 Novartis Bioventures Ltd AGLE Common Stock S - Sale D 10,1100 -15.548 -157 2.295.376
2018-03-26 2018-03-22 4 Magovcevic Ivana AGLE Director Stock Option (right to buy) A - Award D 10,50 36.800 36.800
2018-02-22 2018-02-20 4 Schuchart Aaron AGLE Employee Stock Option (right to buy) A - Award D 6,31 20.000 20.000
2018-02-22 2018-02-20 4 Quinn Anthony AGLE Employee Stock Option (right to buy) A - Award D 6,31 178.400 178.400
2018-02-22 2018-02-20 4 York Charles N II AGLE Employee Stock Option (right to buy) A - Award D 6,31 92.100 92.100
2018-02-22 2018-02-20 4 Wooldridge James AGLE Employee Stock Option (right to buy) A - Award D 6,31 45.000 45.000
2018-02-20 2018-02-15 4 Quinn Anthony AGLE Director Stock Option (right to buy) M - Exercise D 5,46 -15.211 8.598
2018-02-20 2018-02-15 4 Quinn Anthony AGLE Common Stock M - Exercise D 5,4600 15.211 83 50.620
2017-12-08 2017-12-08 4 Quinn Anthony AGLE Common Stock P - Purchase D 5,0650 600 3 35.409
2017-12-08 2017-12-07 4 Quinn Anthony AGLE Common Stock P - Purchase D 4,9882 2.800 14 34.809
2017-12-08 2017-12-06 4 Quinn Anthony AGLE Common Stock P - Purchase D 4,9248 4.888 24 32.009
2017-12-05 2017-12-01 4 Cox Russell J. AGLE Director Stock Option (right to buy) A - Award D 4,73 30.000 30.000
2017-12-05 2017-12-01 4 GEORGIOU GEORGE AGLE Director Stock Option (right to buy) A - Award D 4,73 30.000 30.000
2017-12-05 2017-12-01 4 Mahatme Sandesh AGLE Director Stock Option (right to buy) A - Award D 4,73 30.000 30.000
2017-12-05 2017-12-05 4 Quinn Anthony AGLE Common Stock P - Purchase D 4,9310 5.065 25 27.121
2017-12-05 2017-12-04 4 Quinn Anthony AGLE Common Stock P - Purchase D 4,9804 7.956 40 22.056
2017-12-05 2017-12-01 4 Quinn Anthony AGLE Common Stock P - Purchase D 4,5312 4.100 19 14.100
2017-12-05 2017-12-01 4 Shanafelt Armen AGLE Director Stock Option (right to buy) A - Award D 4,73 30.000 30.000
2017-12-05 2017-12-05 4 York Charles N II AGLE Common Stock P - Purchase D 4,7554 10.241 49 34.787
2017-12-05 2017-12-04 4 York Charles N II AGLE Common Stock P - Purchase D 4,9699 3.259 16 24.546
2017-12-05 2017-12-01 4 York Charles N II AGLE Common Stock P - Purchase D 4,5931 6.500 30 21.287
2017-12-05 2017-08-15 4 York Charles N II AGLE Common Stock P - Purchase D 2,5160 1.959 5 14.787
2017-12-05 2017-02-15 4 York Charles N II AGLE Common Stock P - Purchase D 4,2840 2.000 9 12.828
2017-12-05 2016-08-15 4 York Charles N II AGLE Common Stock P - Purchase D 3,9870 2.000 8 10.828
2017-09-01 2017-08-31 4 Quinn Anthony AGLE Employee Stock Option (right to buy) A - Award D 4,11 150.000 150.000
2017-08-24 2017-08-22 4 Rowlinson Scott W AGLE Employee Stock Option (right to buy) A - Award D 3,10 25.000 25.000
2017-08-24 2017-08-22 4 Schuchart Aaron AGLE Employee Stock Option (right to buy) A - Award D 3,10 10.000 10.000
2017-08-24 2017-08-22 4 TYLER JOSEPH E AGLE Employee Stock Option (right to buy) A - Award D 3,10 25.000 25.000
2017-08-24 2017-08-22 4 Wooldridge James AGLE Employee Stock Option (right to buy) A - Award D 3,10 10.000 10.000
2017-08-24 2017-08-22 4 Wooldridge James AGLE Employee Stock Option (right to buy) A - Award D 3,10 165.000 165.000
2017-08-24 2017-08-22 4 York Charles N II AGLE Employee Stock Option (right to buy) A - Award D 3,10 58.500 58.500
2017-06-20 2017-06-16 4 Schuchart Aaron AGLE Employee Stock Option (right to buy) A - Award D 3,50 100.000 100.000
2017-04-25 2017-04-21 4 Quinn Anthony AGLE Employee Stock Option (right to buy) A - Award D 7,04 24.000 24.000
2017-03-22 2017-03-20 4 TYLER JOSEPH E AGLE Employee Stock Option (right to buy) A - Award D 8,03 39.000 39.000
2017-03-22 2017-03-20 4 York Charles N II AGLE Employee Stock Option (right to buy) A - Award D 8,03 90.000 90.000
2017-03-22 2017-03-20 4 Hebel Henry AGLE Employee Stock Option (right to buy) A - Award D 8,03 38.200 38.200
2017-03-22 2017-03-20 4 Lowe David George AGLE Employee Stock Option (right to buy) A - Award D 8,03 160.000 160.000
2017-03-22 2017-03-20 4 Rowlinson Scott W AGLE Employee Stock Option (right to buy) A - Award D 8,03 60.000 60.000
2017-02-21 2017-02-21 4 ORBIMED ADVISORS LLC See Footnotes AGLE Common Stock P - Purchase I 5,3600 7.000 38 1.469.524
2017-02-21 2017-02-17 4 ORBIMED ADVISORS LLC See Footnotes AGLE Common Stock P - Purchase I 5,1900 71.800 373 1.462.524
2017-02-21 2017-02-16 4 ORBIMED ADVISORS LLC See Footnotes AGLE Common Stock P - Purchase I 5,0400 30.500 154 1.390.724
2017-02-16 2017-02-15 4 Bruhn Suzanne Louise AGLE Director Stock Option (right to buy) A - Award D 5,04 82.000 82.000
2016-05-19 2016-05-17 4 Cox Russell J. AGLE Director Stock Option (right to buy) A - Award D 7,28 10.000 10.000
2016-05-19 2016-05-17 4 Lowe David George AGLE Employee Stock Option (right to buy) A - Award D 7,28 160.000 160.000
2016-05-19 2016-05-17 4 Mahatme Sandesh AGLE Director Stock Option (right to buy) A - Award D 7,28 10.000 10.000
2016-05-19 2016-05-17 4 TYLER JOSEPH E AGLE Employee Stock Option (right to buy) A - Award D 7,28 33.000 33.000
2016-05-19 2016-05-17 4 York Charles N II AGLE Employee Stock Option (right to buy) A - Award D 7,28 55.000 55.000
2016-05-19 2016-05-17 4 Rowlinson Scott W AGLE Employee Stock Option (right to buy) A - Award D 7,28 47.000 47.000
2016-05-19 2016-05-17 4 Shanafelt Armen AGLE Director Stock Option (right to buy) A - Award D 7,28 24.000 24.000
2016-05-19 2016-05-17 4 Hebel Henry AGLE Employee Stock Option (right to buy) A - Award D 7,28 43.000 43.000
2016-05-19 2016-05-17 4 Rojas-Caro Sandra AGLE Employee Stock Option A - Award D 7,28 200.000 200.000
2016-05-19 2016-05-17 4 GEORGIOU GEORGE AGLE Director Stock Option (right to buy) A - Award D 7,28 24.000 24.000
2016-04-19 3 ISALY SAMUEL D AGLE Common Stock I 2.720.448
2016-04-19 3 ISALY SAMUEL D AGLE Common Stock I 2.720.448
2016-04-19 3 ISALY SAMUEL D AGLE Common Stock I 2.720.448
2016-04-19 3 ISALY SAMUEL D AGLE Common Stock I 2.720.448
2016-04-14 3/A Shanafelt Armen by fund AGLE Common Stock I 57.619
2016-04-14 2016-04-12 4/A LILLY ELI & CO by fund AGLE Common Stock C - Conversion I 2.010.924 2.068.543
2016-04-14 2016-04-12 4 LILLY ELI & CO by fund AGLE Series B Preferred Stock C - Conversion I 0,00 -1.120.448 0
2016-04-14 2016-04-12 4 LILLY ELI & CO by fund AGLE Series A Preferred Stock C - Conversion I 0,00 -890.476 0
2016-04-14 2016-04-12 4 LILLY ELI & CO by fund AGLE Common Stock P - Purchase I 10,0000 500.000 5.000 2.568.543
2016-04-14 2016-04-12 4 LILLY ELI & CO by fund AGLE Common Stock C - Conversion I 2.010.924 2.068.543
2016-04-12 2016-04-12 4 Cox Russell J. AGLE Common Stock P - Purchase D 10,0000 7.000 70 7.000
2016-04-12 2016-04-12 4 Lowe David George By trust AGLE Series B Preferred Stock C - Conversion I 0,00 -2.801 0
2016-04-12 2016-04-12 4 Lowe David George By trust AGLE Series A Preferred Stock C - Conversion I 0,00 -2.857 0
2016-04-12 2016-04-12 4 Lowe David George By trust AGLE Common Stock C - Conversion I 5.658 5.658
2016-04-12 2016-04-12 4 Novartis Bioventures Ltd AGLE Series B Preferred Stock C - Conversion D 0,00 -1.120.448 0
2016-04-12 2016-04-12 4 Novartis Bioventures Ltd AGLE Series A Preferred Stock C - Conversion D 0,00 -890.476 0
2016-04-12 2016-04-12 4 Novartis Bioventures Ltd AGLE Common Stock P - Purchase D 10,0000 300.000 3.000 2.310.924
2016-04-12 2016-04-12 4 Novartis Bioventures Ltd AGLE Common Stock C - Conversion D 2.010.924 2.010.924
2016-04-12 2016-04-12 4 Quinn Anthony AGLE Common Stock P - Purchase D 10,0000 10.000 100 10.000
2016-04-12 2016-04-12 4 TYLER JOSEPH E AGLE Series B Preferred Stock C - Conversion D 0,00 -8.403 0
2016-04-12 2016-04-12 4 TYLER JOSEPH E AGLE Series A Preferred Stock C - Conversion D 0,00 -22.857 0
2016-04-12 2016-04-12 4 TYLER JOSEPH E AGLE Common Stock C - Conversion D 31.260 42.428
2016-04-12 2016-04-12 4 York Charles N II By IRA AGLE Series B Preferred Stock C - Conversion I 0,00 -2.037 0
2016-04-12 2016-04-12 4 York Charles N II By IRA AGLE Series A Preferred Stock C - Conversion I 0,00 -9.523 0
2016-04-12 2016-04-12 4 York Charles N II AGLE Series B Preferred Stock C - Conversion D 0,00 -1.324 0
2016-04-12 2016-04-12 4 York Charles N II By IRA AGLE Common Stock C - Conversion I 11.560 11.560
2016-04-12 2016-04-12 4 York Charles N II AGLE Common Stock C - Conversion D 1.324 8.828
2016-04-12 2016-04-12 4 Rowlinson Scott W By trust AGLE Series B Preferred Stock C - Conversion I 0,00 -11.204 0
2016-04-12 2016-04-12 4 Rowlinson Scott W By trust AGLE Common Stock C - Conversion I 11.204 11.204
2016-04-06 3 Shanafelt Armen By fund AGLE Common Stock I 115.238
2016-04-06 3 Shanafelt Armen By fund AGLE Common Stock I 115.238
2016-04-06 3 Rowlinson Scott W AGLE Common Stock D 33.498
2016-04-06 3 Rowlinson Scott W AGLE Common Stock D 33.498
2016-04-06 3 TYLER JOSEPH E AGLE Common Stock D 22.336
2016-04-06 3 TYLER JOSEPH E AGLE Common Stock D 22.336
2016-04-06 3 GEORGIOU GEORGE Held by GMA Technologies L.L.C. AGLE Common Stock I 574.004
2016-04-06 3 GEORGIOU GEORGE AGLE Common Stock D 547.532
2016-04-06 3 GEORGIOU GEORGE By trust AGLE Common Stock I 514.480
2016-04-06 3 GEORGIOU GEORGE Held by GMA Technologies L.L.C. AGLE Common Stock I 574.004
2016-04-06 3 GEORGIOU GEORGE AGLE Common Stock D 547.532
2016-04-06 3 GEORGIOU GEORGE By trust AGLE Common Stock I 514.480
2016-04-06 3 Lowe David George AGLE Common Stock D 412.764
2016-04-06 3 Lowe David George AGLE Common Stock D 412.764
2016-04-06 3 York Charles N II AGLE Common Stock D 15.008
2016-04-06 3 York Charles N II AGLE Common Stock D 15.008
2016-04-06 3 Torres S. Edward AGLE Common Stock D 115.238
2016-04-06 3 Torres S. Edward AGLE Common Stock D 115.238
2016-04-06 3 Torres S. Edward AGLE Common Stock D 115.238
2016-04-06 3 Torres S. Edward AGLE Common Stock D 115.238
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)
Other Listings
DE:3920 58,50 €
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista